ATTUROS LIMITED

Their core work

Atturos is an Irish SME specializing in predictive diagnostics and precision medicine, particularly protein-based blood tests that help clinicians predict treatment response and disease progression. Their core capability lies in developing predictive algorithms and biomarker-based diagnostic tools for chronic inflammatory and metabolic diseases. They contribute data analytics and predictive modeling expertise to large European health consortia focused on psoriasis, obesity, and endocrine-related conditions.

What they specialise in

How they've shifted over time

Atturos began with a focus on in-vitro biological models and endocrine disruptor screening (SCREENED, 2019), involving advanced lab technologies like 3D cell culture, bioprinting, and organ-on-chip. Their more recent projects (SOPHIA 2020, HIPPOCRATES 2021) show a decisive shift toward clinical predictive analytics — treatment algorithms, patient stratification, and federated health databases. The trajectory moves clearly from laboratory screening toward patient-facing precision medicine tools.

Atturos is moving toward data-driven precision medicine, building predictive tools that match patients to optimal treatments — a growing need across chronic disease management.

How they like to work

Atturos primarily operates as a specialist partner in large research consortia rather than leading them. Their single coordination role was a small SME Phase 1 feasibility study (EUR 50K), while their participant roles involve substantial multi-partner projects. With 68 unique partners across 14 countries, they integrate well into large European consortia and bring focused analytical capabilities to broader clinical research efforts.

Atturos has built an extensive network of 68 unique partners across 14 countries through just 4 projects, reflecting their participation in large health consortia. Their reach spans broadly across Europe with no narrow geographic clustering.

What sets them apart

Atturos occupies a specific niche as a diagnostics SME that bridges biomarker discovery and clinical decision-making. Unlike academic partners who focus on disease mechanisms, Atturos brings a commercialization lens — their founding project was explicitly about strategic planning for market entry of a diagnostic blood test. For consortium builders, they offer a rare combination: an SME with real diagnostic product ambitions that can also contribute predictive analytics to clinical research programs.

Highlights from their portfolio

• HIPPOCRATES
  Their largest funded project (EUR 675K) targeting predictive models for psoriatic arthritis treatment — a major unmet clinical need with direct diagnostic product potential.
• SCREENED
  A technically diverse project combining organoids, bioprinting, and organ-on-chip for thyroid disruptor screening — shows Atturos can operate across advanced biological model technologies.
• OCProDx
  Their only coordinated project and origin story — a Phase 1 feasibility study for commercializing a multiplexed protein diagnostic blood test.